GlassScriptPhysician profile
Charles A Farrington
NPI 1114917655
$4,758.26
in general payments reported to CMS, 2019-2025
25 companies · $379 in 2025
The $379 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $419 · 2021: $690 · 2022: $1,850 · 2023: $928 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,900.22 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $435.45 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.62 | 2019-2023 | Xifaxan |
| Pfizer INC. | $260.81 | 2019-2025 | |
| Celgene Corporation | $256.83 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $233.78 | 2019-2025 | Tremfya |
| Genzyme Corporation | $223.24 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.66 | 2021-2023 | Entyvio, Gattex |
| Boston Scientific Corporation | $179.21 | 2022-2025 | Captivator II |
| Janssen Scientific Affairs, LLC | $120.83 | 2022 | |
| Madrigal Pharmaceuticals | $114.80 | 2025 | Rezdiffra |
| Vivus LLC | $100.96 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $78.37 | 2019-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $64.35 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $61.91 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $47.01 | 2023 | Dupixent |
| Nestle Healthcare Nutrition INC. | $37.86 | 2021-2023 | |
| Gilead Sciences, INC. | $30.53 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $25.08 | 2019 | |
| Daiichi Sankyo INC. | $22.76 | 2022 | |
| Amgen INC. | $19.99 | 2021 | |
| Ethicon US, LLC | $19.66 | 2021 | |
| Endo Pharmaceuticals INC. | $19.19 | 2019 | |
| Braintree Laboratories, INC. | $18.68 | 2021 | |
| Shire North American Group INC | $16.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Farrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.